Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CH3FO2S |
| Molecular Weight | 98.097 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(F)(=O)=O
InChI
InChIKey=KNWQLFOXPQZGPX-UHFFFAOYSA-N
InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
| Molecular Formula | CH3FO2S |
| Molecular Weight | 98.097 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Methanesulfonyl fluoride (SNX 001), a very long-acting CNS-selective acetylcholinesterase inhibitor, was studied as a palliative treatment for senile dementia of the Alzheimer type. This drug successfully completed phase I clinical trials where it showed effectively enhance memory in patients with Alzheimer's disease. However, it appears that further studies were discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. | 2008-08-05 |
|
| In utero methanesulfonyl fluoride differentially affects learning and maze performance in the absence of long-lasting cholinergic changes in the adult rat. | 2008-02 |
|
| Nonenzymatic functions of acetylcholinesterase splice variants in the developmental neurotoxicity of organophosphates: chlorpyrifos, chlorpyrifos oxon, and diazinon. | 2007-01 |
|
| Prenatal exposure to the acetylcholinesterase inhibitor methanesulfonyl fluoride alters forebrain morphology and gene expression. | 2005-08-08 |
|
| Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory deficits in ischemic rats. | 2005-03-15 |
|
| Acceleration of Drosophila melanogaster acetylcholinesterase methanesulfonylation: peripheral ligand D-tubocurarine enhances the affinity for small methanesulfonylfluoride. | 2002-02-20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23116458
In a randomized placebo-controlled phase I study, 3.6 mg, 7.2 mg or 10.8 mg methanesulfonyl fluoride (MSF) were then orally administered to 27 consenting healthy volunteers (aged 50 to 72 years).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:22 GMT 2025
by
admin
on
Mon Mar 31 17:49:22 GMT 2025
|
| Record UNII |
9H250YYY0R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
558-25-8
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
C005109
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
11207
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
DTXSID8060329
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
METHANESULFONYL FLUORIDE
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
DB13058
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
9H250YYY0R
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
6397
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY | |||
|
209-192-2
Created by
admin on Mon Mar 31 17:49:22 GMT 2025 , Edited by admin on Mon Mar 31 17:49:22 GMT 2025
|
PRIMARY |